20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Hims & Hers Health Inc (NYSE:HIMS) reported fourth-quarter FY21 sales growth of 104% year-on-year, to $84.7 million, beating the consensus of $76.79 million.
- The average order value for the quarter was $74. Q4 2021 ending member subscriptions grew 95% year-over-year to 609,000.
- The gross profit margin contracted 400 basis points Y/Y to 73%, and the gross profit rose 94.7% Y/Y to $62.1 million.
- The loss from operations widened to $(21.6) million.
- The company held $247 million in cash and equivalents as of December 31, 2021.
- EPS of $(0.15) missed the analyst consensus of $(0.07).
- The adjusted EBITDA loss widened to $(7.1) million.
- Outlook: Hims & Hers sees Q1 sales of $90 million - $93 million versus the consensus of $77.92 million.
- The company expects FY22 sales of $365 million - $380 million against the consensus of $350.75 million.
- Price Action: HIMS shares are trading higher by 14.5% at $4.78 in premarket on the last check Wednesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!